Beam Therapeutics Inc

자세한 내용은 Beam Therapeutics Inc 회사

Beam Therapeutics Inc. is a biotechnology company developing precision genetic medicines through base editing. The Company's suite of gene editing technologies is anchored by base editing, a technology that is designed to enable precise, predictable and efficient single base changes, at targeted genomic sequences, without making double-stranded breaks in the deoxyribonucleic acid. Its lead programs are focused on sickle cell disease and alpha-1 antitrypsin deficiency, and it is also advancing programs in other genetic diseases, as well as immunology/oncology. Its primary programs include BEAM-101, Engineered Stem Cell Antibody Paired Evasion (ESCAPE), BEAM-302, BEAM-301 and BEAM-201. BEAM-101 is a patient-specific, autologous hematopoietic stem cell (HSC), investigational therapy. ESCAPE is a potentially non-genotoxic approach to HSC transplantation. BEAM-302 is a liver-targeting lipid nanoparticle formulation of base editing reagents. BEAM-201 is an anti-CD7 CAR-T product candidate.

회사 정보

종목 코드 BEAM

회사 이름Beam Therapeutics Inc

상장일Feb 06, 2020

CEOMr. John M. Evans

직원 수483

유형Ordinary Share

회계 연도 종료Feb 06

주소238 Main Street

도시CAMBRIDGE

증권 거래소NASDAQ Global Select Consolidated

국가United States of America

우편 번호02142

전화18573278775

웹사이트https://beamtx.com/

종목 코드 BEAM

상장일Feb 06, 2020

CEOMr. John M. Evans

회사 임원

이름

이름/직위

직위

주식 보유

변동

Dr. Giuseppe Ciaramella, Ph.D.

President

107.78K

-6.45%

Dr. Amy Simon, M.D.

Chief Medical Officer

1.74K

-97.47%

Dr. John M. Maraganore, Ph.D.

Independent Director

--

Dr. Christine P. Bellon, Ph.D.

Chief Legal Officer and Secretary

--

Mr. Sravan K. Emany

Chief Financial and Principal Financial Officer

--

Mr. John M. Evans

Chief Executive Officer, Principal Accounting Officer, Director

--

Mr. Chirfi Guindo

Independent Director

--

Ms. Christi Shaw

Independent Director

--

Dr. Mark C. Fishman, M.D.

Lead Independent Director

--

Mr. Graham K. Cooper

Independent Director

--

이름

이름/직위

직위

주식 보유

변동

Dr. Giuseppe Ciaramella, Ph.D.

President

107.78K

-6.45%

Dr. Amy Simon, M.D.

Chief Medical Officer

1.74K

-97.47%

Dr. John M. Maraganore, Ph.D.

Independent Director

--

Dr. Christine P. Bellon, Ph.D.

Chief Legal Officer and Secretary

--

Mr. Sravan K. Emany

Chief Financial and Principal Financial Officer

--

Mr. John M. Evans

Chief Executive Officer, Principal Accounting Officer, Director

--

수익 분석

FY2025Q1

FY2024

FY2023

FY2022

FY2021

FY2020

FY2019

데이터 없음

지역별USD

이름

수익

비율

United States

7.47M

0.00%

사업별

지역별

데이터 없음

주식 보유 통계

마지막 업데이트: Sat, Aug 16

주주

주주 유형

주주

비율

Fidelity Management & Research Company LLC

12.38%

ARK Investment Management LLC

10.29%

Farallon Capital Management, L.L.C.

9.90%

The Vanguard Group, Inc.

9.58%

BlackRock Institutional Trust Company, N.A.

6.64%

기타

51.21%

주주

비율

Fidelity Management & Research Company LLC

12.38%

ARK Investment Management LLC

10.29%

Farallon Capital Management, L.L.C.

9.90%

The Vanguard Group, Inc.

9.58%

BlackRock Institutional Trust Company, N.A.

6.64%

기타

51.21%

주주 유형

주주

비율

Investment Advisor

55.18%

Hedge Fund

20.88%

Investment Advisor/Hedge Fund

19.51%

Venture Capital

4.81%

Research Firm

3.80%

Individual Investor

1.27%

Bank and Trust

0.67%

Pension Fund

0.28%

Family Office

0.06%

기관 주식 보유

마지막 업데이트: Tue, Jul 1

보고 기간

기관 수

보유 주식

비율

변동

2025Q2

537

101.17M

100.03%

+11.84M

2025Q1

562

100.13M

99.59%

+12.37M

2024Q4

542

80.18M

95.83%

-6.23M

2024Q3

539

78.60M

95.42%

-7.95M

2024Q2

538

78.23M

95.09%

-5.21M

2024Q1

550

76.09M

93.23%

-4.97M

2023Q4

549

75.48M

92.79%

-3.23M

2023Q3

554

74.84M

95.14%

-3.35M

2023Q2

566

72.06M

94.81%

-2.24M

2023Q1

583

68.81M

92.54%

-724.80K

주주 활동

이름

보유 주식

비율

변동

Chg %

날짜

Fidelity Management & Research Company LLC

7.60M

7.56%

+4.49M

+144.60%

Mar 31, 2025

ARK Investment Management LLC

8.48M

8.43%

+1.41M

+19.98%

Mar 31, 2025

Farallon Capital Management, L.L.C.

9.93M

9.87%

+1.69M

+20.50%

Mar 31, 2025

The Vanguard Group, Inc.

8.85M

8.8%

+1.24M

+16.36%

Mar 31, 2025

BlackRock Institutional Trust Company, N.A.

6.76M

6.72%

+838.01K

+14.15%

Mar 31, 2025

Nikko Asset Management Co., Ltd.

4.27M

4.24%

+309.26K

+7.81%

Mar 31, 2025

ARCH Venture Partners

4.54M

4.51%

--

Mar 31, 2025

State Street Global Advisors (US)

3.44M

3.42%

+362.74K

+11.79%

Mar 31, 2025

Bellevue Asset Management AG

2.40M

2.38%

+877.81K

+57.82%

Mar 31, 2025

Kynam Capital Management LP

2.52M

2.5%

+762.01K

+43.39%

Mar 31, 2025

16.860USD

Beam Therapeutics Inc

16.860

개요

회사

금융

분석